60207-19-4

Basic information

• Product Name: 1-(4-chloro-2-methoxyphenyl)ethanone
• Synonyms: 1-(4-chloro-2-methoxyphenyl)ethanone
• CAS NO: 60207-19-4
• Molecular Formula: C₉H₉ClO₂
• Molecular Weight: 184.61956
• Mol File: 60207-19-4.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(4-chloro-2-methoxyphenyl)ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-chloro-2-methoxyphenyl)ethanone(60207-19-4)
• EPA Substance Registry System: 1-(4-chloro-2-methoxyphenyl)ethanone(60207-19-4)

Safety Data

• Hazardous Substances Data: 60207-19-4(Hazardous Substances Data)

Usage

Chemical class

Acetophenone

Physical state

White crystalline solid

Uses

Synthesis of pharmaceuticals, organic compounds, reagent in chemical reactions, building block in complex organic molecule synthesis

Molecular weight

182.62 g/mol

Hazards

Harmful if ingested or inhaled, requires caution during handling

Upstream product

• 6921-66-0 4-chloro-2-hydroxy acetophenone 
• 77-78-1 dimethyl sulfate 
• 205320-02-1 4-chloro-N,2-dimethoxy-N-methylbenzamide 
• 75-16-1 methylmagnesium bromide 
• 57479-70-6 2-methoxy-4-chlorobenzoic acid 
• 13031-39-5 3-chlorophenyl acetate 
• 74-88-4 methyl iodide 
• 7758-89-6 copper(I) chloride 
• 60207-18-3 4'-amino-2'-methoxylacetophenone 
• 100960-68-7 4-chloro-2-methoxylbenzonitrile 
• 3375-31-3 palladium diacetate 
• 755027-21-5 4-chloro-1-iodo-2-methoxybenzene 

Downstream Products

• 6921-66-0 4-chloro-2-hydroxy acetophenone 
• 114741-22-9 7-chloro-4-oxo-4H-chromene-2-carboxylic acid 
• 60208-06-2 2-bromo-2'-methoxy-4'-chloroacetophenone 
• 1354928-59-8 C₁₇H₁₁ClO₄ 
• 1354928-54-3 C₁₇H₁₁ClO₄ 
• 164026-03-3 C₁₁H₁₂ClNO₂ 

Relevant articles and documents

Structure-Based Design of N-(5-Phenylthiazol-2-yl)acrylamides as Novel and Potent Glutathione S-Transferase Omega 1 Inhibitors

Using reported glutathione S-transferase omega 1 (GSTO1-1) cocrystal structures, we designed and synthesized acrylamide-containing compounds that covalently bind to Cys32 on the catalytic site. Starting from a thiazole derivative 10 (GSTO1-1 IC50 = 0.6 μM), compound 18 was synthesized and cocrystallized with GSTO1. Modification on the amide moiety of hit compound 10 significantly increased the GSTO1-1 inhibitory potency. We solved the cocrystal structures of new derivatives, 37 and 44, bearing an amide side chain bound to GSTO1. These new structures showed a reorientation of the phenyl thiazole core of inhibitors, 37 and 44, when compared to 18. Guided by the cocrystal structure of GSTO1:44, analogue 49 was designed, resulting in the most potent GSTO1-1 inhibitor (IC50 = 0.22 ± 0.02 nM) known to date. We believe that our data will form the basis for future studies of developing GSTO1-1 as a new drug target for cancer therapy.

Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents

The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.

Chromenones as potent bradykinin B1 antagonists

A series of fused 6,6-bicyclic chromenones was investigated for activity against the bradykinin B1 receptor. SAR studies based on a pharmacophore model revealed compounds with high affinity for both human and rabbit B1. These compounds demonstrated favorable pharmacokinetic properties and 5-chlorochromenone 15 was efficacious in a carrageenan-induced mechanical hyperalgesia model for chronic pain.

Optimization of chromone-2-carboxamide melanin concentrating hormone receptor 1 antagonists: Assessment of potency, efficacy, and cardiovascular safety

Evaluation of multiple structurally distinct series of melanin concentrating hormone receptor 1 antagonists in an anesthetized rat cardiovascualar assay led to the identification of a chromone-2-carboxamide series as having excellent safety against the chosen cardiovascular endpoints at high drug concentrations in the plasma and brain. Optimization of this series led to considerable improvements in affinity, functional potency, and pharmacokinetic profile. This led to the identification of a 7-fluorochromone-2-carboxamide (22) that was orally efficacious in a diet-induced obese mouse model, retained a favorable cardiovascular profile in rat, and demonstrated dramatic improvement in effects on mean arterial pressure in our dog cardiovascular model compared to other series reported by our group. However, this analogue also led to prolongation of the QT interval in the dog that was linked to affinity for hERG channel and unexpectedly potent functional blockade of this ion channel.

Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor

The present invention is directed to compounds of formula (I), which antagonize of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders.

HETEROCYCLIC KINASE INHIBITORS

Compounds having the formula (I) are useful for inhibiting protein kinases. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

Therapeutic agents useful for treating inflammatory diseases

This invention relates to compounds of formula I and pharmaceutically acceptable salts thereof STR1 in which R1, R2 and R3 independently represent hydrogen, halo, alkyl, alkoxy, phenoxy, phenyl, alkoxycarbonyl, --NR13 R14, halogenated alkoxy, halogenated alkyl, benzyloxy, hydroxy, hydroxyalkyl, (C2-6 alkoxycarbonyl)vinyl, --S(O)n R7, carbamoylalkyl, alkoxycarbonylalkyl, --CONR11 R12, or R1 and R2 together with the phenyl ring represent a naphthyl group; R4 and R5 independently represent hydrogen, alkyl, phenyl or together with the carbon atom represent C3-6 cycloalkyl; R6 represents hydrogen, alkyl or ω-hydroxy alkyl; A represents C2-9 alkylene; R8 represents hydrogen, alkyl, halo, alkoxy, hydroxyalkyl, benzyl or phenyl; R9 and R10 independently represent hydrogen, alkyl, halo, alkoxy, phenyl, hydroxyalkyl, alkoxycarbonyl, nitro, --NR30 R31, alkanoyloxyalkyl, or aminomethyl; which are antiinflammatory and antiallergic agents. Compositions containing these compounds and processes to make them are also disclosed.

Infrared study of polysubstitution effects in benzophenones and acetophenones: contribution of inter and intracycle interaction mechanisms

The carbonyl stretching frequencies of substituted 2-Me, 2,6-diMe, 2-MeO benzophenones and 2-Me, 2-MeO acetophenones have been measured in diluted CCl4 solutions.Two interaction mechanisms are observed.In X, Y substituted benzophenones with X on the same cycle as the ortho group and Y on the other cycle, it is shown that for X=Y, the effect of Y is greater than that of X except for very strong electron-releasing substituents.In this last case, the observed enhancement is attributed to the joint effects of intercycle interactions excercised on X and Y and of intracycle interaction on X.These results are corroborated by the study of substituted acetophenones in which only the intracycle mechanism can play a role.

Antimicrobial and plant-growth-regulating triazole derivatives

Novel 1-(β-aryl)ethyl-1H-1,2,4-triazole ketals useful for their antimicrobial and plant-growth regulating activities.

Triazole derivatives

Novel 1-(β-aryl)ethyl-1H-1,2,4-triazole ketals useful for their antimicrobial and plant-growth regulating activities.